About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNANCT04833335

ASL in Brain Metastasis MRI Following Gamma Knife Treatment

Arterial spin labeling (ASL) is a non-invasive MRI technique that could help the radiologists to distinguish brain metastasis progression versus radionecrosis following gamma-knife treatment. The pri...

Lead sponsor: Assistance Publique - Hôpitaux de Paris•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Natalia SHOR, MD

CONTACT

+330661884335 shor.natalia@icloud.com

Sponsors

Lead Sponsor

Assistance Publique - Hôpitaux de Paris

The metastasis progression versus radionecrosis following GK treatment can sometimes be difficult to distinguish. 60 patients will be included in this prospective, monocentric study. 3 MRI (baseline, 1month and 6 month follow-ups) will be performed. Two neuroradiologists will blindly analyse the MRIs comparing ASL sensibility and specificity to the standard morphological evaluation and T2 perfusion.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Brain metastasis from histologically proven tumor
•GK treatment within 4 month prior to the inclusion
•Lesions suspected of progression/ radionecrosis :
•i.e.≥ 25% of the size progression
•Lesion size: gadolinium enhanced part of the tumour ≥1 cm

Exclusion Criteria

•Pregnancy
•Medical history of primitive brain tumour
•MRI incompatibility/ medical history of contrast agent allergy
•Claustrophobia
•Patient unable to consent
•Epilepsia/recent stroke
•Patients participating in other studies
•Patients without health care insurance

Related studies

RECRUITINGPhase 2

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

NCT07462507 · Central Nervous System Cancer, Brain Metastases

RECRUITINGPhase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

NCT06253871 · HER2 Mutation-Related Tumors, HER2, and more

RECRUITINGPhase 1/2

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

NCT05987644 · Lung Cancer, NSCLC, and more

RECRUITINGPhase 2

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

NCT05692635 · Brain Metastases, Nonsmall Cell Lung Cancer Stage III

RECRUITINGPhase 2

Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

NCT07130786 · Seizures, Primary Motor Cortex, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 8, 2025Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment60

Start dateJan 2023

Last updatedAug 8, 2025

Condition

Brain Metastases

Locations shown

Service de neuroradiologie, hôpital Pitié Salpêtrière

Paris

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 8, 2025Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions